Introduction {#s1}
============

The specification of tissues and organs in development depends upon the spatially and temporally accurate execution of gene expression programs, much of which is regulated at the level of transcription. The factors involved in the accurate transcription of eukaryotic structural genes by RNA polymerase II can be classified into two groups. First, general (or basic) transcription factors (GTFs) are necessary and can be sufficient for accurate transcription initiation in vitro (for review, see [@bib41]). These basic factors include RNA polymerase II itself and at least six GTFs: TFIID, TFIIA, TFIIB, TFIIE, TFIIF and TFIIH. The GTFs assemble on the core promoter in an ordered fashion to form a pre-initiation complex (PIC).

Transcriptional activity is greatly stimulated by the second class of factors, promoter-specific activator proteins (activators). In general, activators are sequence-specific DNA-binding proteins whose recognition sites are typically present upstream of the core promoter. Activators work in large part by increasing PIC formation but can also act through other mechanisms, such as accelerating the rate of transcriptional elongation, promoting multiple rounds of transcription and directing chromatin modifications (reviewed in [@bib17]; [@bib14]; [@bib45]).

A long-held view of transcription activation is that specificity arises from the differential expression and activity of activators, which function through the common basic transcription machinery. However, it is now clear that the differential expression and use of basic transcription factors can also contribute to eukaryotic gene regulation (reviewed in [@bib8]; [@bib20]). This notion is most dramatically illustrated by a variety of studies focused on the GTF TFIID, a multi-subunit complex composed of the TATA-box-binding protein (TBP) and a set of ∼14 TBP-associated factors (TAFs).

One of the earliest clues about the differential function of TFIID came from studies in yeast demonstrating distinct classes of protein-coding genes that differ by their dependence on and recruitment of TAFs ([@bib23]; [@bib25]). Subsequently, similar classes of TAF-dependent and -independent genes were identified in mammalian cells ([@bib36]; [@bib42]). Consistent with the existence of TAF-independent promoters, more recent studies have found that TAFs are depleted upon terminal differentiation of muscle ([@bib10]; [@bib9]) and liver ([@bib6]). TFIID diversity is also promoted by tissue-specific variants of TAFs as well as TBP derivatives referred to as TBP-related factors (reviewed in [@bib7]; [@bib29]).

Human embryonic stem cells (hESCs) are a good example of a specialized cell type that is regulated by a unique transcriptional network. Two characteristic properties of hESCs, pluripotency, a capacity to differentiate into all fetal and adult cell lineages, and the ability to undergo symmetrical self-renewing divisions, are largely controlled at the transcriptional level (reviewed in [@bib4]). In undifferentiated hESCs, pluripotency genes such as *OCT4* (also called *POU5F1*), *NANOG* and *SOX2* are expressed, whereas genes involved in differentiation are transcriptionally inactive (reviewed in [@bib39]; [@bib33]). Decreased expression of pluripotency genes induces differentiation ([@bib31]), and thus proper transcriptional regulation is essential for self-renewal of undifferentiated hESCs.

Despite intense efforts to identify hESC-specific activators involved in the transcriptional regulatory network of pluripotency, there has been relatively little analysis of GTFs in general and TFIID in particular. Here we find that both the composition and promoter occupancy patterns of hESC TAFs are highly unusual. We go on to show that this selective expression and use of TAFs establishes a transcriptional program required for hESC self-renewal.

Results {#s2}
=======

Undifferentiated hESCs express only a subset of TFIID TAFs {#s2-1}
----------------------------------------------------------

In a search of published expression datasets ([@bib1]), we found that several TAFs of the canonical TFIID complex were apparently not expressed in hESCs. To investigate this possibility, we analyzed expression of 13 TAFs by immunoblotting lysates from H9 cells, a well-characterized hESC line. As a control, we also analyzed TAF expression in HeLa cells, which have been extensively used to study TFIID composition and function. The immunoblot of [Figure 1A](#fig1){ref-type="fig"} shows, as expected, that all 13 TAFs were expressed in HeLa cells. By contrast, hESCs clearly expressed TAFs 2, 3, 5, 6, 7 and 11, whereas expression of TAFs 1, 4, 8, 9, 10, 12, and 13 was undetectable. Interestingly, TAF6 is expressed in both cell types, but the isoform present in H9 cells is predominantly the short delta form, whereas in HeLa cells, the major TAF6 isoform is the larger, alpha/beta form. The specificity of each TAF antibody was confirmed by RNA interference (RNAi)-mediated knockdown ([Figure 1---figure supplements 1 and 2](#fig1s1 fig1s2){ref-type="fig"}). We observed a similar TAF expression pattern in a second hESC line, H1 cells ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Quantitative RT-PCR (qRT-PCR) analysis comparing *TAF* mRNA levels in HeLa and H9 cells correlated with the immunoblotting results ([Figure 1B](#fig1){ref-type="fig"}). Unlike the TAFs, all other GTFs analyzed were comparably expressed in HeLa and H9 cells ([Figure 1C](#fig1){ref-type="fig"}). Based upon these results we conclude that only six of the canonical TFIID TAFs are present in hESCs.10.7554/eLife.00068.003Figure 1.Undifferentiated hESCs express only a subset of TFIID TAFs.(**A**) Immunoblot analysis showing TAF levels in HeLa cells and H9 hESCs. β-actin (ACTB) was monitored as a loading control. (**B**) qRT-PCR analysis monitoring *TAF* expression in H9 cells relative to HeLa cells. A ratio of 1 (indicated by the red dotted line) indicates no difference in expression. Data are represented as mean ± SEM. (**C**) Immunoblot analysis showing levels of GTFs in HeLa cells and H9 hESCs. α-tubulin (TUBA) was monitored as a loading control. (**D**) Immunoblots showing TAF and TBP levels in H9 hESCs following induction of differentiation by retinoic acid treatment for 0, 3 or 6 days. OCT4 and NES were monitored as controls.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.003](10.7554/eLife.00068.003)10.7554/eLife.00068.004Figure 1---figure supplement 1.Confirmation of specificity of TAF antibodies by RNAi-mediated knockdown in H9 hESCs.Immunoblot analysis showing TAF levels in H9 hESCs 48 hr after transfection with a control luciferase (Luc) or TAF siRNA. β-actin (ACTB) was monitored as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.004](10.7554/eLife.00068.004)10.7554/eLife.00068.005Figure 1---figure supplement 2.Confirmation of specificity of TAF antibodies by RNAi-mediated knockdown in HeLa cells.Immunoblot analysis showing TAF levels in HeLa cells 48 hr after transfection with a control luciferase (Luc) or TAF siRNA. β-actin (ACTB) was monitored as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.005](10.7554/eLife.00068.005)10.7554/eLife.00068.006Figure 1---figure supplement 3.TAF expression levels in H1 hESCs.Immunoblot analysis showing TAF levels in H1 hESCs and, as a comparison, H9 hESCs and HeLa cells. β-actin (ACTB) was monitored as a loading control. The results demonstrate an identical pattern of TAF expression in both H9 and H1 hESCs.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.006](10.7554/eLife.00068.006)

We next asked whether differentiation of hESCs results in a change in TAF composition. Toward this end, H9 cells were treated with retinoic acid to induce differentiation and TAF expression was analyzed by immunoblotting. [Figure 1D](#fig1){ref-type="fig"} shows, as expected, that following retinoic acid treatment, expression of the pluripotency factor OCT4 was lost and NES, a neuroectoderm marker, was induced. Significantly, TAFs 1, 4, 8, 9, 10, 12, and 13, which are not expressed in undifferentiated H9 cells, were induced following retinoic acid treatment. TAFs 2, 3, 5, 6, 7 and 11, which are expressed in undifferentiated H9 cells, were also present at a relatively constant level following retinoic acid treatment.

hESCs have a non-canonical TBP-containing TAF complex {#s2-2}
-----------------------------------------------------

To investigate whether the six hESC TAFs were associated in a stable complex, H9 cell nuclear extract was fractionated by sucrose gradient sedimentation and individual fractions analyzed for TAFs 2, 3, 5, 6, 7 and 11 by immunoblotting. The results of [Figure 2A](#fig2){ref-type="fig"} show that TAFs 2, 6, 7 and 11 co-sedimented with an apparent native molecular mass of ∼440 kDa. By contrast, TAFs 3 and 5 fractionated heterogeneously, and a substantial portion of both TAFs had an apparent molecular mass consistent with that of the free proteins (∼140 and ∼100 kDa, respectively). As expected, TBP, which is associated with multiple complexes involved in transcription by all three RNA polymerases, fractionated heterogeneously. Notably, however, a peak of TBP co-sedimented with TAFs 2, 6, 7 and 11.10.7554/eLife.00068.007Figure 2.hESCs have a non-canonical TBP-containing TAF complex.(**A**) Sucrose gradient sedimentation. H9 cell nuclear extract was fractionated, and individual fractions were analyzed for TAFs by immunoblotting. Arrows indicate elution peaks of protein standards. (**B**) Co-immunoprecipitation analysis. Nuclear extracts from H9 cells were immunoprecipitated with an anti-TBP or control (anti-RAB2A) antibody and the immunoprecipitate was analyzed for TAFs and TBP by immunoblotting.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.007](10.7554/eLife.00068.007)

To provide additional evidence for a stable, multi-subunit TAF complex, and to determine whether TBP was a component, we performed co-immunoprecipitation experiments. TBP was immunoprecipitated from H9 cell nuclear extracts, and the immunoprecipitate was analyzed by immunoblotting for the six hESC TAFs. The results of [Figure 2B](#fig2){ref-type="fig"} show that TBP was stably associated with TAFs 2, 6, 7 and 11 but not TAFs 3 and 5. Collectively, these results indicate that H9 cells contain a non-canonical TAF complex composed of TBP and TAFs 2, 6, 7 and 11 but not TAFs 3 and 5.

Two classes of active hESC genes based on TAF promoter occupancy {#s2-3}
----------------------------------------------------------------

The results of the expression analysis and biochemical experiments implied that the PIC formed on the promoters of active genes in hESCs would have an atypical TAF composition. To investigate this issue, we performed a series of chromatin immunoprecipitation (ChIP) experiments. In the first set of experiments we selected 10 transcriptionally active genes and performed ChIP analysis to monitor promoter occupancy by the six hESC TAFs. As a normalization standard, we also monitored occupancy of TBP and RNA polymerase II large subunit (POL2) on these 10 promoters. As expected, we found that TBP and POL2 were present at comparable levels at each of the 10 promoters ([Figure 3A](#fig3){ref-type="fig"}). However, the absolute level of TBP and POL2 bound to each promoter significantly varied among the 10 genes. Therefore, in this experiment and those presented below, TAF recruitment was normalized to the level of TBP occupancy. The ChIP results of [Figure 3B](#fig3){ref-type="fig"} revealed two groups of genes with distinct TAF promoter occupancy patterns. The first group, which we refer to as class I genes, were bound by TAFs 3 and 5 but not by TAFs 2, 6, 7 and 11, whereas the second group, class II genes, were bound by all six hESC TAFs.10.7554/eLife.00068.008Figure 3.Two classes of hESC genes based on TAF promoter occupancy.(**A**) Recruitment of TBP and POL2 to the promoters of 10 transcriptionally active genes (*GAPDH*, *INTS6*, *MORF4L2*, *SLC25A3*, *TBP*, *TP53*, *FSCN1*, *OCT4*, *PCNA*, *SFPQ*), each represented by a data point, were monitored by ChIP in H9 cells. For each gene, enrichment of TBP or POL2 binding to the promoter was normalized to a no antibody control and for non-specific recruitment at a control locus. (**B**) ChIP analysis monitoring TAF recruitment to the promoters of the 10 genes in H9 cells. TAF recruitment is specified relative to TBP recruitment (which was set to 1), after normalizing to a no antibody control and for non-specific recruitment to a control gene desert locus. Data are represented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.008](10.7554/eLife.00068.008)

To support this conclusion, we also compared TAF occupancy in HeLa and H9 cells across seven class I genes that are transcriptionally active in both cell types ([Figure 4A](#fig4){ref-type="fig"}). As a control, we first analyzed a representative subset of TAFs that are expressed in HeLa but not H9 cells. The ChIP analysis of [Figure 4B](#fig4){ref-type="fig"} shows that TAFs 1, 8 and 9 were readily detected on the promoters of genes in HeLa cells but, as expected, not H9 cells. Next, we analyzed the six TAFs that are expressed in both HeLa and hESCs. [Figure 4C](#fig4){ref-type="fig"} shows that in both cell types TAFs 3 and 5 were recruited to the promoters of the seven genes. By contrast we found that TAFs 2, 6, 7 and 11 were bound to the promoters of the seven genes in HeLa but not in H9 cells ([Figure 4C](#fig4){ref-type="fig"}). These results indicate that on the same transcriptionally active gene the TAF composition is strikingly different in HeLa and H9 cells.10.7554/eLife.00068.009Figure 4.Comparison of TAF promoter occupancy on an identical set of transcriptionally active genes in HeLa and H9 cells.(**A**) Recruitment of TBP and POL2 to the promoters of seven class I genes (*EEF1A1*, *FOS*, *GAPDH*, *SLC25A3*, *TBP*, *TLE4* and *TP53*) were monitored by ChIP in HeLa and H9 cells. Data were normalized as described in [Figure 3A](#fig3){ref-type="fig"}. (**B**) ChIP analysis monitoring recruitment of TAFs 1, 8 and 9 to the promoters of the seven class I genes in HeLa and H9 cells, as described in (**A**). Data are represented as mean ± SD. (**C**) ChIP analysis monitoring recruitment of TAFs 2, 3, 5, 6, 7 and 11 to the promoters of the seven class I genes in HeLa and H9 cells, as described in (**A**). Data are represented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.009](10.7554/eLife.00068.009)

We next performed a series of RNAi experiments to determine the relationship between TAF occupancy and transcriptional activity. The qRT-PCR results of [Figure 5A](#fig5){ref-type="fig"} show that siRNA-mediated knockdown of TAFs 3 and 5 in H9 cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) greatly reduced expression of both class I and II genes. By contrast, siRNA-mediated knockdown of TAFs 2, 6, 7 and 11 decreased expression of class II, but did not affect expression of class I genes ([Figure 5B](#fig5){ref-type="fig"}). Comparable results were obtained with a second, unrelated siRNA directed against each of the six TAFs ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Collectively, these results establish a strong relationship between TAF occupancy and transcriptional activity in hESCs.10.7554/eLife.00068.010Figure 5.A strong relationship between TAF occupancy and transcriptional activity in hESCs.(**A**) qRT-PCR analysis monitoring expression of class I and II genes in H9 TAF3 or TAF5 knockdown (KD) cells. Normalized Ct values were analyzed after subtracting the signal obtained with the control RN18S1 shRNA (see 'Materials and methods'). Data are represented as mean ± SEM. (**B**) qRT-PCR analysis monitoring expression of class I and II genes in H9 TAF2, 6, 7, or 11 KD cells. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.010](10.7554/eLife.00068.010)10.7554/eLife.00068.011Figure 5---figure supplement 1.siRNA-mediated knockdown efficiency of TAFs in H9 hESCs.qRT-PCR analysis monitoring *TAF* expression in H9 cells treated with two independent siRNAs (**A**) directed against the indicated TAF. TAF expression is specified relative to that obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.011](10.7554/eLife.00068.011)10.7554/eLife.00068.012Figure 5---figure supplement 2.Confirmation of TAF requirement for transcriptional activity using a second, unrelated siRNA.qRT-PCR analysis monitoring expression of class I and class II genes in H9 cells treated with a TAF3, TAF5, TAF2, TAF6, TAF7 or TAF11 siRNA. Expression of each gene is specified relative to that obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.012](10.7554/eLife.00068.012)

Global ChIP-chip analysis of TAF occupancy in hESCs {#s2-4}
---------------------------------------------------

To confirm and extend the ChIP results, we performed global ChIP-chip analyses. In these experiments we monitored, in parallel, promoter occupancy of TAFs 3 and 5, TAFs 7 and 11 (as representative members of the TBP/TAF 2,6,7,11 complex), TBP and POL2. The overall results are summarized in [Figure 6](#fig6){ref-type="fig"}. We first defined a group of ∼3600 high-confidence actively transcribed genes based upon co-occupancy of both TBP and POL2 at the transcription start-site ([Figure 6---figure supplements 1--3](#fig6s1 fig6s2 fig6s3){ref-type="fig"}). The vast majority of active genes had promoter-bound TAF3 and TAF5 ([Figure 6A](#fig6){ref-type="fig"}). Significantly, a smaller fraction of active genes had promoter-bound TAF7 or TAF11, and there was substantial overlap between TAF7- and TAF11-bound genes ([Figure 6B](#fig6){ref-type="fig"}). As expected, the vast majority of genes bound by TAFs 7 and 11 were also bound by TAFs 3 and 5 ([Figure 6C](#fig6){ref-type="fig"}). Representative examples of promoter occupancy maps for two class I (*SLC25A3*, *CCNB2*) and class II (*SFPQ*, *UCHL1*) genes are shown in [Figure 6D](#fig6){ref-type="fig"}.10.7554/eLife.00068.013Figure 6.Global ChIP-chip analysis of TAF occupancy.(**A**) Venn diagram showing the overlap between TBP-, POL2-, TAF3- and TAF5-bound genes. (**B**) Venn diagram showing the overlap between TBP-, POL2-, TAF7- and TAF11-bound genes. (**C**) Venn diagram showing the overlap between TAF3- and TAF5-bound genes and TAF7- and TAF11-bound genes. (**D**) Representative maps showing TAF3, TAF5, TAF7, TAF11, TBP and POL2 occupancy at the promoters of class I (*SLC25A3* and *CCNB2*) and class II (*SFPQ* and *UCHL1*) genes. (**E**) Differences between class I and II genes with respect to promoter H3K4me3. (**F**) Differences between class I and II genes with respect to average number of alternative promoters per ChIP-enriched site. (**G**) Representative promoter occupancy maps for two class II genes with alternative promoters, *IFRD1* and *CSF2RA*.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.013](10.7554/eLife.00068.013)10.7554/eLife.00068.014Figure 6---figure supplement 1.Location of TBP, POL2 and TAF occupancy relative to the transcription start site.Histograms showing binding of TBP, POL2 and TAFs as a function of distance to the nearest transcription start site (TSS). The results show that binding of TBP, POL2 or a TAF occurred predominantly near the TSS.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.014](10.7554/eLife.00068.014)10.7554/eLife.00068.015Figure 6---figure supplement 2.ChIP-chip peak overlap in independent replicates.Venn diagrams showing the degree of overlap between two independent replicates of the ChIP experiment. The number of peaks in each group are indicated by brackets.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.015](10.7554/eLife.00068.015)10.7554/eLife.00068.016Figure 6---figure supplement 3.Co-occupancy of TBP and POL2 with TAFs.Venn diagrams showing the degree of overlap between the number of genes whose promoters are bound by TBP and POL2, and the number bound by a given TAF.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.016](10.7554/eLife.00068.016)

To validate the ChIP-chip results, we selected a representative set of 44 genes and performed directed ChIP experiments using promoter-specific primer pairs. These validation experiments, which are shown in [Figure 7](#fig7){ref-type="fig"}, confirmed the predicted TAF occupancy patterns for ≥85% of the genes tested. For example, consistent with the ChIP-chip results, there was no significant binding (i.e., no enrichment relative to the no antibody negative control) of TBP or TAFs 3, 5, 7 or 11 to a group of inactive promoters predicted by the ChIP-chip analyses to not be bound by these factors ([Figure 7A](#fig7){ref-type="fig"}). Most importantly, [Figure 7B](#fig7){ref-type="fig"} shows that TAF7 occupancy validated at 24 of 27 predicted sites (88.9%), TAF11 occupancy at 27 of 28 predicted sites (96.4%), TAF3 occupancy at 36 of 39 predicted sites (92.3%), and TAF5 occupancy at 39 of 39 predicted sites (100.0%).10.7554/eLife.00068.017Figure 7.Validation of ChIP-chip results by directed ChIP experiments using promoter-specific primer pairs.(**A**) ChIP analysis monitoring binding of TBP and TAFs 3, 5, 7 and 11 to a representative set of promoters that, based on ChIP-chip analyses, were predicted not to be bound by these factors. The results were normalized to a no antibody control (which was set to 1). Data are represented as mean ± SEM. For four genes (*THOC1*, *CBWD3*, *RBM39* and *ZNF260*), the inactive promoter (A2) was analyzed in (**A**), and the active promoter (A1) was analyzed in (**B**) and (**C**). (**B**) ChIP analysis monitoring binding of TAFs 3, 5, 7 and 11 to the promoters of a representative set of 47 genes predicted by the ChIP-chip analyses to be bound by some or all of the factors. Data are normalized to TBP. Cutoff for a 'positive' is \>0.4-fold enrichment vs TBP (red line). Data are represented as mean ± SEM. (**C**) ChIP analysis monitoring binding of TAF2 and TAF6 to 19 promoters that are bound by TAF7 and TAF11. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.017](10.7554/eLife.00068.017)

[Figure 7B](#fig7){ref-type="fig"} also shows that the overlap between TAF7- and TAF11-bound genes was higher than that predicted by the ChIP-chip analyses. Specifically, the results show that TAF7 was present at 7 of 7 predicted TAF11-only sites, and TAF11 was present at 5 of 6 predicted TAF7-only sites, indicating that TAF7 and 11 co-occupancy was 12 of 13 (92.3%).

Moreover, as expected, genes bound by TAFs 7 and 11 were also co-occupied by TAFs 2 and 6 ([Figure 7C](#fig7){ref-type="fig"}). For example, of the 16 promoters analyzed that were bound by TAF7 and TAF11, TAF2 was present at 16 and TAF6 was present at 15 of these promoters. Collectively, the ChIP-chip analyses, in conjunction with the results described above, confirm the existence of two groups of genes in hESCs whose promoters are bound either only by TAFs 3 and 5 (class I genes) or by all six hESC TAFs (class II genes).

Finally, we analyzed the ChIP-chip dataset in relation to previous genome-wide studies in hESCs ([@bib1]; [@bib2]; [@bib18]) for features that might distinguish class I and class II genes and found two statistically significant differences ([Figure 6E,F](#fig6){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). First, the promoters of class I genes had greater histone H3 lysine 4 trimethylation (H3K4me3) than those of class II genes ([Figure 6E](#fig6){ref-type="fig"}). Second, the fraction of genes with alternative promoters (identified based upon UCSC Genome Browser annotations; see 'Materials and methods') was significantly higher for class II than for class I genes ([Figure 6F](#fig6){ref-type="fig"}). Representative examples of promoter occupancy maps for two class II genes with alternative promoters are shown in [Figure 6G](#fig6){ref-type="fig"}.10.7554/eLife.00068.018Table 1.Statistical analysis of ChIP-chip data**DOI:** [http://dx.doi.org/10.7554/eLife.00068.018](10.7554/eLife.00068.018)FeatureAll TBP + POL2 sitesClass I genes (p-value vs TBP + POL2)Class II genes (p-value vs TBP + POL2)p-value (Class I vs Class II)Alternative promoters (average number)0.7170.686 (0.008)0.934 (2.64 × 10^−67^)1.73 × 10^−58^Bidirectional promoters (percent)23.96125.315 (0.005)28.186 (0.007)0.110Promoter occupancy (percent)H3K4me391.48289.214 (8.72 × 10^−05^)82.721 (4.24 × 10^−20^)1.16 × 10^−13^OCT43.6843.919 (0.728)3.064 (1.000)0.293NANOG12.43813.448 (0.006)13.725 (0.698)0.861SOX210.24311.471 (9.64 × 10^−05^)11.642 (0.474)0.901Promoter elements (percent)TATA box4.8346.365 (5.15 × 10^−15^)7.353 (0.012)0.335BRE88.99992.413 (6.27 × 10^−24^)92.892 (0.001)0.650Initiator99.60899.928 (0.000)100.000 (1.000)0.402MTE0.6790.611 (1.000)0.735 (1.000)0.626DCE99.84399.964 (0.422)99.877 (1.000)0.402

The composition of hESC TAFs is required for proper regulation of gene expression and maintenance of the undifferentiated state {#s2-5}
-------------------------------------------------------------------------------------------------------------------------------

Finally, we analyzed whether the unusual composition of TAFs was important for the characteristic ability of hESCs to maintain an undifferentiated state and self-renew. [Figure 8A](#fig8){ref-type="fig"} shows that shRNA-mediated knockdown of each of the six hESC TAFs ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) induced differentiation, as evidenced by a decreased percentage of alkaline phosphatase-positive colonies. To confirm this conclusion, we also tested whether knocking down hESC TAFs would induce differentiation by analyzing expression of a diverse set of differentiation markers: AFP (endoderm), CGB7 (trophoectoderm), IGF2 (mesoderm), NES (ectoderm) and SOX1 (neuroectoderm). [Figure 8B](#fig8){ref-type="fig"} shows that depletion of each hESC TAF resulted in up-regulation, to varying extents, of these differentiation markers. Comparable results were obtained with a second, unrelated shRNA or siRNA directed against each of the six TAFs ([Figure 8---figure supplements 2 and 3](#fig8s2 fig8s3){ref-type="fig"}). Finally, the induction of differentiation following knockdown of hESC TAFs was also evidenced by decreased expression of the pluripotency genes *NANOG* ([Figure 8C](#fig8){ref-type="fig"} and [Figure 8---figure supplement 4](#fig8s4){ref-type="fig"}) and *OCT4* ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Thus, the hESC TAFs are required to maintain the undifferentiated state.10.7554/eLife.00068.019Figure 8The composition of hESC TAFs is required for maintenance of the undifferentiated state.(**A**) Percent of H9 TAF knockdown (KD) colonies staining with alkaline phosphatase. Data are represented as mean ± SD. (**B**) qRT-PCR analysis monitoring expression of differentiation markers (*AFP*, *CGB7*, *IGF2*, *NES* and *SOX1*) in H9 cells treated with a TAF siRNA. Values are relative to those obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SEM. (**C**) qRT-PCR analysis monitoring expression of *NANOG* in H9 cells treated with a TAF siRNA. Values are relative to those obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SEM. (**D**) qRT-PCR analysis monitoring *TAF1* expression in H9 cells transfected with a plasmid expressing *TAF1* or, as a control, empty vector. Expression of *TAF1* was monitored 48 hr following transfection. *TAF1* expression is specified relative to that obtained with the empty vector, which was set to 1. Data are represented as mean ± SEM. (**E**) Alkaline phosphatase staining of H9 colonies ectopically expressing TAF1 or, as a control, vector. Data are represented as mean ± SD. (**F**) qRT-PCR monitoring expression of differentiation markers (*AFP*, *CGB7*, *IGF2*, *NES* and *SOX1*) in H9 cells ectopically expressing TAF1. Values are relative to those obtained in H9 cells expressing vector, which was set to 1. Data are represented as mean ± SEM. (**G**) qRT-PCR monitoring expression of class I and II genes in H9 cells ectopically expressing TAF1. Data are represented as mean ± SEM. (**H**) Immunoblot analysis showing OCT4 levels in H9 cells over-expressing TAFs, TBP or vector. (**I**) ChIP analysis monitoring recruitment of TBP, POL2 and TAF1 to the *OCT4* promoter in H9 cells ectopically expressing TAF1 or vector. Data are represented as mean ± SD. (**J**) Schematic model. Some of the protein interactions shown are arbitrary.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.019](10.7554/eLife.00068.019)10.7554/eLife.00068.020Figure 8---figure supplement 1.shRNA-mediated knockdown efficiency of TAFs in H9 hESCs.qRT-PCR analysis monitoring *TAF* expression in H9 cells treated with two independent shRNAs directed against the indicated TAF. TAF expression is specified relative to that obtained with a control non-silencing shRNA, which was set to 1. Data are represented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.020](10.7554/eLife.00068.020)10.7554/eLife.00068.021Figure 8---figure supplement 2.Validation of results presented in [Figure 8A](#fig8){ref-type="fig"} using a second, unrelated shRNA.Percent of H9 TAF knockdown (KD) colonies staining with alkaline phosphatase. Data are represented as mean ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.021](10.7554/eLife.00068.021)10.7554/eLife.00068.022Figure 8---figure supplement 3.Validation of results presented in [Figure 8B](#fig8){ref-type="fig"} using a second, unrelated siRNA.qRT-PCR analysis monitoring expression of differentiation markers in H9 cells treated with a TAF siRNA. Values are given relative to that obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.022](10.7554/eLife.00068.022)10.7554/eLife.00068.023Figure 8---figure supplement 4.Validation of results presented in [Figure 8C](#fig8){ref-type="fig"} using a second, unrelated siRNA.qRT-PCR analysis monitoring expression of *NANOG* in H9 cells treated with a TAF siRNA. Values are given relative to that obtained with a control luciferase siRNA, which was set to 1. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.023](10.7554/eLife.00068.023)

In a reciprocal set of experiments, we altered TAF composition by ectopically expressing a TAF that is not normally present in hESCs. We found that ectopic expression of TAF1 ([Figure 8D](#fig8){ref-type="fig"}) resulted in differentiation, as evidenced by a decreased number of alkaline phosphatase-positive colonies ([Figure 8E](#fig8){ref-type="fig"}), the induction of differentiation markers ([Figure 8F](#fig8){ref-type="fig"}, left), and decreased expression of *NANOG* ([Figure 8F](#fig8){ref-type="fig"}, right). Interestingly, [Figure 8G](#fig8){ref-type="fig"} shows that ectopic TAF1 expression decreased expression of several class II genes, including as expected *OCT4*, whereas expression of class I genes was either unaffected or in some instances increased modestly. Ectopic expression of several other TAFs not present in hESCs also resulted in loss of expression of *OCT4*, a class II gene, but not *ACTB*, a class I gene ([Figure 8H](#fig8){ref-type="fig"}). By contrast, ectopic expression of TBP or TAFs that are present in hESCs did not affect OCT4 levels. To investigate the basis for the decreased *OCT4* expression, we performed ChIP analysis. [Figure 8I](#fig8){ref-type="fig"} shows that, following ectopic expression of TAF1, TBP and POL2 were no longer recruited to the *OCT4* promoter. Collectively, the results of [Figure 8](#fig8){ref-type="fig"} show that altering the composition of hESC TAFs results in misregulation of gene expression and induction of differentiation.

Discussion {#s3}
==========

In this report we have shown that the general transcription machinery of hESCs is highly unusual in that approximately half of the canonical TFIID TAFs are not detectably expressed. The absence of TAFs was confirmed by multiple, independent experimental approaches including immunoblotting ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), qRT-PCR ([Figure 1B](#fig1){ref-type="fig"}) and ChIP ([Figure 4B](#fig4){ref-type="fig"}). Previous studies have reported tissue-specific TAF variants and alterations in TAF expression (reviewed in [@bib7]; [@bib29]), but the composition of hESC TAFs is unprecedented and is likely highly specific, if not unique, to hESCs. For example, we find that mouse ESCs, which bear both similarities and differences to hESCs ([@bib15]; [@bib46]; [@bib37]), express all TFIID TAFs analyzed ([Figure 9](#fig9){ref-type="fig"}), consistent with the results of a recent study that focused on the role of TAF3 in mouse ESCs ([@bib27]).10.7554/eLife.00068.024Figure 9.TAF expression in mouse ESCs.Immunoblot analysis monitoring TAF levels in PGK12.1 mouse ESCs and, as a control, HeLa cells. ACTB was monitored as a loading control. The results show that TAFs 1, 4, 8, 9, 10 and 13, which are not expressed in hESCs, are expressed in mouse ESCs.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.024](10.7554/eLife.00068.024)

Following submission of our manuscript, the Encyclopedia of DNA Elements (ENCODE) consortium released an extensive set of genome-wide analyses including ChIP-Sequencing (ChIP-Seq) results for TAF1 in H1 hESCs (<http://encodeproject.org/ENCODE/>), implying that TAF1 is present in H1 cells. Notably, all but one of our experiments were performed in another hESC line, H9 cells. In the one experiment performed in H1 cells, we compared TAF levels in H1 and H9 cells by immunoblotting ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The pattern of TAF expression in H1 and H9 cells was qualitatively similar but the experiment could not rule out the possibility that TAF1 was present at low levels in H1 cells, which could explain the ENCODE ChIP-Seq results.

It is also possible that in the H9 cells used in our studies TAF1, as well as TAFs 4, 8, 9, 10, 12 and 13, are not entirely absent but rather present at low levels, which are below that we can detect in an immunoblotting assay. However, if H9 cells do contain low levels of TAFs 1, 4, 8, 9, 10, 12 and 13 our biochemical experiments indicate that they are below that required to stably associate with TBP and the TAFs that are detectably present in H9 cells to form the much larger TFIID complex ([Figure 2A](#fig2){ref-type="fig"}). In addition, we could not detect significant binding of TAFs 1, 8 and 9 on the promoters of seven transcriptionally active genes in H9 cells in a ChIP assay, although binding was readily detected on the same promoters in HeLa cells ([Figure 4B](#fig4){ref-type="fig"}). Thus, our conclusion that H9 cells contain no (or very low levels of) TAFs 1, 4, 8, 9, 10, 12 and 13 is based not only on expression data but also on biochemical results and promoter binding experiments.

A novel TBP-containing TAF complex in undifferentiated hESCs {#s3-1}
------------------------------------------------------------

The absence of seven of the conventional TFIID TAFs suggested that hESCs contain an alternative TBP-containing complex. Our ChIP and biochemical experiments confirmed this possibility and revealed a model in which a stable complex containing TBP and TAFs 2, 6, 7 and 11 is recruited to active class II genes, and TAFs 3 and 5 are recruited independently to all active genes ([Figure 8J](#fig8){ref-type="fig"}). Notably, this novel TBP-containing complex lacks TAF1, which in the canonical TFIID complex interacts directly with TBP ([@bib3]), and TAF4, which is essential for assembly of *Drosophila* TFIID ([@bib48]). However, consistent with the existence of a TBP/TAF 2,6,7,11 complex, previous studies have described interactions between TBP and TAF2 ([@bib44]), TAF6 ([@bib47]) and TAF11 ([@bib24]), and between TAF7 and TAF11 ([@bib24]).

Previous studies have shown that nine of the 14 TFIID TAFs contain a sequence motif homologous to histones, called the histone fold domain (HFD), which mediates protein--protein interactions (reviewed in [@bib5]; [@bib34]). These nine TAFs can form five specific heterodimers: TAF3--10, TAF6--9, TAF4--12, TAF8--10 and TAF11--13. Several of these heterodimers are thought to be important for the assembly and structure of TFIID. hESCs contain only three HFD-containing TAFs (3, 6 and 11), which cannot form any of the five known heterodimers. This observation strongly suggests there are major differences in assembly and structure of TFIID and the TBP/TAF 2,6,7,11 complex.

An important question raised by our results is the basis by which TAFs are differentially recruited to class I or class II promoters. Studies in yeast have shown that differential recruitment of TAFs can be due to promoter-bound activators, core promoter elements, or both ([@bib38]; [@bib26]). In this regard, TAF2 and TAF6 have been shown to interact with promoter sequence elements (reviewed in [@bib28]), which may contribute to differential promoter recognition by the TBP/TAF 2,6,7,11 complex. In addition, TAF3 contains a PHD finger domain that can bind to the H3K4me3 chromatin mark ([@bib43]), which is enriched at class I promoters ([Figure 6E](#fig6){ref-type="fig"}).

Understanding the basis by which basic transcription factors are differentially recruited to promoters on a genome-wide scale appears to be a particularly challenging problem. For example, it is still not understood what distinguishes TAF-dependent and TAF-independent promoters in yeast ([@bib23]; [@bib25]), why some basic transcription factors, such as mediator, are bound at only some promoters ([@bib13]), or the basis by which chromatin-modifying complexes are selectively recruited to promoters ([@bib30]).

Another question arising from our findings is whether there are functional differences that distinguish class I and class II genes. Gene ontology analysis did not reveal any functional category that was differentially enriched in either class I or class II genes (data not shown). For example, although several pluripotency factors including OCT4 ([Figure 3B](#fig3){ref-type="fig"}) and NANOG ([Figure 10](#fig10){ref-type="fig"}) are encoded by class II genes, we found other pluripotency factors, such as SOX2, DPPA4 and KLF4, that are encoded by class I genes ([Figure 10](#fig10){ref-type="fig"}). There was, however, a statistically significant increase in alternative promoters at class II genes ([Figure 6F](#fig6){ref-type="fig"}). Notably, alternative promoter use has been suggested to play a role in generating tissue-specific transcripts ([@bib21]; [@bib22]; [@bib32]).10.7554/eLife.00068.025Figure 10.Classification of additional pluripotency genes as either class I or class II.ChIP analysis monitoring TAF recruitment to the promoters of four pluripotency genes in H9 cells. TAF recruitment is specified relative to TBP recruitment (which was set to 1), after normalizing to a no antibody control and for non-specific recruitment to a control gene desert locus. Data are represented as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.00068.025](10.7554/eLife.00068.025)

Our ChIP experiments show that genes that are broadly expressed, such as housekeeping genes, can be activated by diverse core promoter recognition complexes in different cell types ([Figure 4C](#fig4){ref-type="fig"}), revealing a remarkable plasticity of the transcription machinery. The core promoter sequence is identical in every cell, raising the possibility that in hESCs differences in activators or epigenetic signatures may be coordinated with the alterations in core promoter complexes. For example, in the myogenic program, core promoter recognition complex changes correlates with the presence of developmentally regulated activators ([@bib9]).

The selective expression and use of TAFs is required for hESC self-renewal {#s3-2}
--------------------------------------------------------------------------

We have found that altering the composition of hESC TAFs, either by RNAi-mediated knockdown of TAFs that are present or ectopic expression of TAFs that are absent, results in loss of pluripotency gene expression and induction of differentiation. Thus, the unusual composition of TAFs described here is required for the ability of hESCs to properly regulate gene expression, maintain an undifferentiated state, and self-renew. This conclusion is reinforced by the finding that the TAFs that are absent from undifferentiated hESCs are expressed following differentiation ([Figure 1D](#fig1){ref-type="fig"}). The transcriptional induction of several differentiation markers, which are not normally expressed in hESCs, following knockdown of an hESC TAF can be explained either by the dispensability of the TAF for transcription of the marker, or incomplete knockdown enabling transcription to occur at reduced TAF levels.

A characteristic feature of the switch of undifferentiated hESCs to the differentiated state is the loss of pluripotency gene expression. We have shown that ectopic expression of TAFs that are not present in undifferentiated hESCs results in transcriptional inactivation of pluripotency genes. Thus, the transcriptional induction of TFIID TAFs that are absent from undifferentiated hESCs may be at least part of the mechanism by which pluripotency genes are silenced following differentiation.

As discussed above, previous studies have shown that terminal differentiation of muscle ([@bib10]) and liver ([@bib6]) is accompanied by loss of TFIID TAFs. These and other findings have prompted speculation that during differentiation the canonical TFIID complex becomes progressively specialized (reviewed in [@bib7]). However our results reveal a more complex model. Rather than starting from a complete, canonical TFIID and progressing to more restricted forms, undifferentiated hESCs start with a specialized, highly unique general transcription machinery, then switch to a period of complete TFIID before specialization of the transcription machinery again in some terminal differentiation programs. Collectively, these findings suggest that altering the composition of the basic transcription machinery in general and TAFs specifically may be a particularly powerful mechanism for developmental reprogramming.

Materials and methods {#s4}
=====================

Cell lines and culture {#s4-1}
----------------------

H9 (WA09) and H1 (WA01) hESCs were obtained from the UMass Human Stem Cell Bank and Registry. Cell lines were cultured on irradiated mouse feeder cells using DMEM/F12 media supplemented with KnockOut SR (Invitrogen, Carlsbad, CA) and basic FGF (R&D Systems, Minneapolis, MN), and cultures were karyotyped every 10--15 passages. All hESCs used were between passages 40--65. hESCs for ChIP experiments were harvested 5--6 days after passage to ensure high density, such that the mouse feeder cells represented less than ∼12% of the total material (similar to what has been used in previously published hESC ChIP experiments; [@bib2]). For [Figure 1D](#fig1){ref-type="fig"}, H9 cells were passaged using Accutase (STEMCELL Technologies, Vancouver, Canada) and plated without feeders in DMEM containing 10% FBS and 1 µM all-trans retinoic acid (Sigma, St. Louis, MO). For transfections, H9 cells were grown in mTesR1 media (STEMCELL Technologies) under feeder-free conditions on plates coated with Matrigel (BD Biosciences, San Jose, CA). HeLa cells were maintained in DMEM supplemented with 10% FCS at 37°C and 5% CO~2~. The mouse ESC line PGK12.1, provided by N. Brockdorff, was cultured as previously described ([@bib35]).

Immunoblot analysis {#s4-2}
-------------------

Cells were trypsinized, pelleted, and washed twice in PBS. Nuclei were isolated by incubating the cell pellet in lysis buffer \[10 mM Pipes-K+ pH 6.9, 0.2% NP-40, 5 mM KCl, 1.5 mM MgCl~2~, 2 µM ZnSO~4~, 5% glycerol, 2% PEG 2000, plus 1 mM PMSF; Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland) and phosphatase inhibitors (Sigma P2850 and P5726)\] for 2 min on ice, and pelleted by centrifugation. Nuclei were resuspended in nuclear extract buffer (NEB1: 25 mM PIPES pH 6.9, 0.2% Tween 20, 0.4 M NaCl, 1.5 mM MgCl~2~, 2 µM ZnSO~4~, 5% glycerol, 2% PEG 2000, plus 1 mM PMSF; Complete Protease Inhibitor Cocktail and phosphatase inhibitors) for 10 min on ice, followed by centrifugation to remove nuclear debris. Protein content of the nuclear extracts was measured by BCA assay. Nuclear extracts were separated on either 8% or 12% SDS-PAGE gels. Blots were probed with primary antibodies (listed in [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}) overnight at 4°C, washed five times in TBP plus 0.1% Tween (TBST) and then incubated with the appropriate HRP-conjugated secondary antibody for 1 hr at room temperature. Membranes were washed five times in TBST and visualized on autoradiography film after incubating with ECL reagent (Supersignal West Pico or Supersignal West Femto; Thermo Scientific, Waltham, MA).

Quantitative RT-PCR {#s4-3}
-------------------

Total RNA was isolated using TRIzol (Invitrogen), then treated with DNase I (Promega, Fitchburg, WI) and repurified using RNeasy columns (Qiagen, Hilden, Germany). Reverse transcription was performed using the SuperScript II Reverse Transcription Kit (Invitrogen) with random oligo priming, followed by quantitative real-time PCR using Platinum SYBR Green qPCR SuperMix-UDG with Rox (Invitrogen) on either an ABI 7500 or StepOne Plus Real-Time PCR System (Applied Biosystems, Carlsbad, CA). Primer sequences are listed in [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}. For all reactions, inputs were normalized and the Ct values of samples were analyzed after subtracting the signal obtained with the non-silencing shRNA (for RNAi) or no antibody (for ChIP) controls. For TAF knockdown experiments, human 18S rRNA (*RN18S1*) was used as the endogenous control, because its expression should not be affected by changes in TAF expression.

Sucrose gradient sedimentation {#s4-4}
------------------------------

Sucrose gradient sedimentation analysis was performed as described ([@bib40]). Briefly, 10--40% gradients were formed by layering 500 µl NEB1 (see 'Immunoblot analysis') containing 10%, 20%, 30%, or 40% sucrose in a 11 × 34-mm centrifuge tube (Beckman, Brea, CA) and allowed to equilibrate at room temperature for 2 hr. Gradients were chilled, loaded with either 500 µg H9 nuclear extract (adjusted to a volume of 200 µl) or 200 µl molecular weight markers (Sigma MW-GF-1000), and centrifuged in a Beckman TLS-55 rotor at 50,000 rpm (214,000×*g*) for 12 hr. Twenty-three fractions of ∼90 µl were collected. For the markers, 20 µl of each fraction was electrophoresed and Coomassie stained. For the H9 gradient fractions, 25 µl of even-numbered fractions were analyzed by immunoblotting.

Co-immunoprecipitation {#s4-5}
----------------------

H9 nuclear extract (600 µg) was incubated with 6 µg of anti-TBP antibody (Santa Cruz, Santa Cruz, CA) at overnight at 4°C. Immune complexes were captured on rabbit TrueBlot IP beads (eBioScience, San Diego, CA), washed three times in NEB1, and eluted by boiling 10 min in 2× SDS sample buffer. IP material was then analyzed for the presence of TAFs by immunoblotting (see [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}), using the Rabbit IgG TrueBlot HRP-conjugated secondary antibody (eBioScience).

ChIP and ChIP-chip assays {#s4-6}
-------------------------

Cells were dual-cross-linked with ethylene glycolbis\[succinimidyl succinate\] (EGS), and formaldehyde as described ([@bib49]). Chromatin shearing and ChIP experiments were then performed essentially as reported ([@bib19]), with slight modifications. For each ChIP experiment, 500 µg chromatin (based on BCA assay) was pre-cleared with BSA- and ytRNA-blocked protein G agarose beads (Millipore, Billerica, MA). The pre-cleared supernatant was then incubated with 5 µg of primary antibody (see [Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}) at 4°C overnight. Immune complexes were precipitated with protein G-agarose beads, washed, eluted, and purified as described. ChIP products were analyzed by qRT-PCR using primers listed in [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}. Real-time PCR results were analyzed using QBasePlus software (Biogazelle, Zwijnaarde, Belgium). Site-specific relative fold changes of ChIP-enriched samples were calculated by comparing the amplification threshold (Ct) value of a given ChIP sample at a specific target locus (promoter) with the amplification Ct of a no-antibody control at the same target locus being analyzed, and also with the same ChIP sample and no-antibody control sample Ct values at a non-recruiting control locus found in a gene desert on human chromosome 16 (primers 'GDM' in [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}).

For ChIP-chip, 200 ng of ChIP-enriched or no-antibody control chip DNA fragments were blunted using End-It DNA End-Repair Kit (Epicentre Biotechnologies, Madison, WI), then ligated to unidirectional linkers (annealed oligos oJW102: 5′-GCGGTGACCCGGGAGATCTGAATTC and oJW103: 5′-GAATTCCAGATC) using Fast-link DNA ligation kit (Epicentre Biotechnologies). Linker-adapted DNA was amplified for 18 rounds using high-fidelity Pfu polymerase, then purified. DNA was labeled with either Cy5-dCTP (chip samples) or Cy3-dCTP (no antibody control) in a second PCR amplification of 18 rounds. The labeled DNAs were purified on QIAquick columns (Qiagen) and the incorporation was checked by spectrophotometry. 20 pmol of each labeled DNA (chip and control) was combined and used to hybridize to a Human ChIP-chip 3 × 720K RefSeq Promoter Array (Roche NimbleGen, Madison, WI) using a hybridization kit, sample tracking controls, wash buffer kit and array processing accessories from NimbleGen. Arrays were scanned on an Agilent Scanner at 5 µm resolution. Data were analyzed to identify peaks of binding using Nimblescan software (Roche NimbleGen) with default settings. Further analysis of ChIP data was conducted using ChipPeakAnno ([@bib50]). The list of sites were filtered to remove multiple peaks occurring in the same promoter, which resulted in a set of genes whose promoters are bound by each factor. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus ([@bib11]) and are accessible through GEO Series accession number GSE39312 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39312>). Promoter maps shown in [Figure 6](#fig6){ref-type="fig"} were generated using the UCSC Genome Browser ([genome.ucsc.edu](http://genome.ucsc.edu)).

For alternative promoter analyses, our ChIP-chip datasets were compared with the AltEvents track on the UCSC Genome Browser to find the frequency of overlap between chip peaks and 'AltPro' annotations. For comparison with H3K4me3, we used previously published data ([@bib18]) after converting that dataset to HG18 coordinates using Galaxy ([@bib16]). Statistical significance of differences in occurrence was determined using Fisher\'s exact test.

RNA interference {#s4-7}
----------------

For transient siRNA transfections, 30 pmol of siRNA duplexes (see [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}) was mixed with 5 µl Lipofectamine RNAiMAX and OptiMEM Reduced-Serum media (Invitrogen) in a total volume of 500 µl, incubated for 20 min, and added to H9 cells 1 day after plating in a six-well plate (i.e., at ∼25% confluency) along with 2.5 ml fresh media. After 48 hr, RNA was isolated or nuclear extract prepared. For stable shRNA knockdowns, H9 cells seeded in a six-well plate to 25% confluency were stably transduced with 200-µl lentiviral particles expressing shRNAs (obtained from Open Biosystems through the UMMS RNAi Core Facility; see [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}) in a total volume of 2 ml of mTesR1 media supplemented with 6 µg/ml polybrene. Media was replaced after overnight incubation to remove the polybrene and viral particles.

Alkaline phosphatase staining {#s4-8}
-----------------------------

Alkaline phosphatase staining was performed using the Alkaline Phosphatase Staining Kit (Stemgent, Cambridge, MA). To assess differentiation, 500 colonies were evaluated for AP staining and the percent positively stained was calculated. All assays were performed in triplicate.

Ectopic TAF expression {#s4-9}
----------------------

Full-length open reading frames of human *TAF* genes were PCR-amplified from HeLa cDNA and cloned in-frame into pECFP vector (Clontech Laboratories, Mountain View, CA). Junctions were sequenced to confirm the construction. For transfection, 2 µg plasmid was mixed with 6 µl FuGENE HD Transfection Reagent (Roche) and OptiMEM in a total volume of 100 µl, incubated for 15 min, and then added to H9 cells in a six-well plate at 25% confluency. After 48 hr, RNA was isolated or nuclear extract prepared.
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Thank you for choosing to send your work entitled "Non-canonical TAF Complexes Regulate Active Promoters in Human Embryonic Stem Cells" for consideration at *eLife*. Your article has been evaluated by a Senior Editor and 3 reviewers, two of whom are members of *eLife\'s* Board of Reviewing Editors. The following individuals responsible for the peer review of your submission want to reveal their identity: Jim Kadonaga; Danny Reinberg.

The Reviewing Editor and two other reviewers discussed their comments before we reached this decision, and the Reviewing Editor has assembled the following comments based on the reviewers\' reports. Our goal is to provide the essential revision requirements as a single set of instructions, so that you have a clear view of the revisions that are necessary for us to publish your work.

In this study, the authors investigated the function of the TAFs (TBP-associated factors) in human embryonic stem cells (hESCs). The conventional/canonical TFIID complex comprises TBP and about 14 TAF subunits. In this work, it was found that TAFs 2, 3, 5, 6, 7, and 11 - but not TAFs 1, 4, 8, 9, 10, 12, and 13 - are expressed in hESCs, and that TAFs 2, 6, 7, and 11 appear to form a novel complex with TBP. By ChIP analysis, two classes of transcriptionally active genes were identified in hESCs. Class I genes are regulated by TAFs 3 and 5, whereas Class II genes are regulated by all six TAFs in hESCs. RNAi depletion of TAF 2, 3, 5, 6, 7, or 11 as well as overexpression of TAF1 caused a decrease in pluripotency. These findings suggest that the proper regulation of TAFs is important for the maintenance of hESCs.

These results reveal that a subset of the pol II TAFs are expressed in hESCs, and that the specific expression of these TAFs is important for the maintenance of pluripotency. The analysis was rigorous, comprehensive, and convincing. The findings are novel, and of high impact and general interest. This work will be appropriate for publication in *eLife* if the following points are suitably addressed.

1\. Fig. 5. Does the knockdown of one TAF affect the occupancy of other TAFs and RNA pol II at the genes analyzed? If such information is available, it would be a useful addition to the paper.

2\. Fig. 6E. The range of the Y axis should be from 0 to 100 percent. This would give a better perspective on the data.

3\. Fig. 6F. The range of the Y axis should be from 0.0 to 1.0. The authors should also explain what criteria were used to determine whether or not a gene has alternate promoters.
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Author response

*1. The reviewer commented that, if the information were available, the results of RNA polymerase II and TAF recruitment would be a useful addition to the shRNA-mediated knockdown experiments of Figure 5*.

For different reasons, as explained below, neither of the two datasets mentioned by the reviewer is available.

With regard to RNA polymerase II recruitment, a number of previous studies by our laboratory and others have analyzed the relationship between TAF dependence and RNA polymerase II occupancy in vivo. Notably, these studies have been carried out in a wide range of eukaryotes including yeast, Drosophila S2 cells and mammalian cells. The results of these studies have clearly demonstrated that when a TAF is required for transcription of a gene, loss-of-function of that TAF (resulting from mutational inactivation, RNA interference-mediated depletion or decreased expression) results in diminished transcription that is accompanied by decreased RNA polymerase II occupancy in a chromatin-immunoprecipitation (ChIP) assay. Representative examples of such studies include those performed in yeast (Shen et al. 2003, *EMBO J*. 22:3395; Sharma et al. 2003, *Genes Dev*. 17:502), Drosophila S2 cells (Vorobyeva et al. 2009, *PNAS* 106:11049) and mammalian cells (Deato and Tjian 2007, *Genes Dev*. 21:2137; Zaborowska et al. 2012, *Transcription* 3:92). In addition to these in vivo examples, several in vitro studies have also demonstrated a role for TAFs in RNA polymerase II recruitment (see, for examples, Wu and Chiang 2001, *J. Biol. Chem*. 276:34235; Felinski and Quinn 2001, *PNAS* 98:13078).

Therefore, because the relationship between TAF dependence and RNA polymerase II occupancy had been well established, this issue was not investigated in our current study.

With regard to TAF recruitment, we are in fact actively studying the requirement of specific TAFs for recruitment of other TAFs and TBP at class I and class II promoters. We believe that when these results are completed they may provide insights into the roles of specific TAFs in transcription of class I and class II genes and shed light on the differences between class I and class II promoters. However, our preliminary results indicate that the requirement of specific TAFs for recruitment of other TAFs and TBP is complex, differs among the TAFs, and may also differ between promoters of the same class. Therefore, until we have performed a comprehensive analysis, which will require considerably more experimentation and time and may necessitate genome-wide studies, we think it would premature to publish a limited set of results, which could be potentially non-representative and misleading.

*2. The reviewer requested that we revise Figure 6E so that the Y-axis ranges from 0 to 100 percent to provide a better perspective on the data*.

We have revised the figure as requested by the reviewer.

*3. The reviewer requested that we revise Figure 6F so that the Y-axis ranges from 0.0 to 1.0. He/she also asked that we explain the criteria used to determine whether or not a gene has an alternative promoter*.

We have revised the figure as requested by the reviewer. The criteria we used to determine whether a gene has an alternative promoter is described in detail in the Materials and Methods section. Prompted by the reviewer\'s comment, we have revised the main text describing Figure 6F to briefly state that alternative promoters were identified based on UCSC Genome browser annotations, and refer the reader to the Materials and Methods section for additional details.
